GlobeNewswire by notified

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis


(Phase II Multicenter Study is Proceeding Well with High Anticipation)

AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.

XBiotech believes Natrunix will be a breakthrough therapy for rheumatological diseases. The company has now enrolled about 33% of the 210 patients it is recruiting for a Phase II, Double-Blind, Placebo-Controlled, Randomized study, examining Natrunix in combination with methotrexate for the treatment of Rheumatoid Arthritis. There are presently about 25 clinical trial sites across the United States that are participating in the study. Dr. Kivitz, who is actively treating subjects at his clinic in Altoona, Pennsylvanian commented, “Despite all the breakthroughs in our ability to treat Rheumatoid Arthritis there continues to be an unmet need for some patients with this disease. I am excited to be part of a clinical trial program studying a novel approach to RA.”

Dr. Kivitz has had a prodigious medical career treating arthritis and rheumatic diseases. He received his medical degree from Albany Medical College, New York, trained in internal medicine at the North Shore University Hospital and Memorial Sloan Kettering Cancer in New York and then completed rheumatology studies at Albany Medical College. Dr. Kivitz has authored over 500 research articles, abstracts, and clinical studies relating to osteoarthritis, osteoporosis and rheumatoid arthritis and has lectured on his findings around the world. Dr. Kivitz has served on advisory boards for major drug developers, including AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Pfizer, Regeneron Pharmaceuticals, Sanofi-Genzyme, Takeda, and UCB. Above all Dr. Kivitz is focused on finding new approaches to treat arthritis and rheumatic disorders.

John Simard, President and CEO of XBiotech commented, “We are honored to have Dr. Kivitz chair this study for which we are eagerly anticipating results.”

Nearly forty-years ago investigators began to describe a key role for interleukin-1 in cartilage destruction and disease progression in arthritis and degenerative arthropathies1.2 Indeed finding biological therapies to target interleukin-1 was an initial impetus for the nascent biotechnology industry in the late 1980s. But confusion over the nature of the interleukin-1 meant that therapies designed to target its activity failed to hit the mark for all potential disease indications.

The confusion about interleukin-1 is highlighted by the fact that there is in reality no such substance as interleukin-1! Rather, interleukin-1 actually refers to two separate and distinct molecules—IL-α and IL-1β —each playing unique roles in health and disease. The α and β Interleukin-1 molecules are chemically and physically distinct and under different genetic and post transcriptional regulation. The α and β molecules are thus deployed with disparate temporal and spatial distribution and with unique biological functions. Nonetheless, despite great anticipation for blocking “interleukin-1” activity clinically, no therapeutic besides Natrunix has been developed to specifically and exclusively block IL-1α activity in rheumatology.

Natrunix exclusively and specifically blocks IL-1α. Targeting IL-1α is crucial, since it may be the key interleukin-1 potentiator of pain and inflammation in affected tissues in affected joints. Natrunix is not only unique in how it targets interleukin-1, it also extraordinary because it is a monoclonal antibody (unlike any other marketed therapeutic antibody) derived from a naturally occurring immunoglobulin—identified from a healthy human donor with natural immunity to IL-1α. XBiotech calls Natrunix a True Human Antibody.

About XBiotech

XBiotech is pioneering the discovery and development of targeted antibodies based on its True Human™ technology. The company’s mission is to discover and commercialize its pipeline of truly natural human antibodies for treating serious diseases such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. XBiotech’s has several candidate products including those that specifically block the activity of interleukin-1 alpha (IL-1α). Cloned from individual donors who possess natural immunity against certain targeted diseases, XBiotech’s pipeline of True Human antibodies are intended to deliver unmatched safety and efficacy. At the Company’s 48-acre campus, located just minutes from downtown Austin, XBiotech has a fully integrated biopharma headquarters, including biological GMP manufacturing facilities, research and QC testing laboratories, quality and clinical operations. For more information, visit

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


Wenyi Wei
Tel. 737-207-4600 

1 Bunning et al. The effect of interleukin-1 on connective tissue metabolism and its relevance to arthritis Agents Actions Suppl. 1986:18:131-52.
2 Vershure & Van Noorden. The effects of interleukin-1 on articular cartilage destruction as observed in arthritic diseases, and its therapeutic control. Clin Exp Rheumatol. 1990 May-Jun;8(3):303-13.

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Vow ASA: Full year and second half of 2023 results28.2.2024 23:11:51 CET | Press release

Oslo, 28 February 2024: Vow ASA (OSE: VOW) revenues for the full year 2023 were NOK 918.5 million, a 17 per cent increase from the year before. EBITDA before non-recurring items was negative NOK 23.4 million for the full year. In addition, the company recorded non-recurring items of negative NOK 31.3 million, mainly related to non-cash balance sheet clean-up in contract accruals. This resulted in a negative EBITDA for the year of NOK 54.7 million versus a positive NOK 85.5 million in 2022. “The year 2023 was a year of high activity and revenue. A large number of projects were successfully delivered. Activity in aftersales was increasing. We also secured important new contracts and moved into position for new projects in new industry verticals,” said Henrik Badin, CEO of Vow ASA. At the end of 2023, the order backlog was NOK 1 034 million and another NOK 921 million in options. The backlog and options are providing visibility for revenues and good margins well into 2025/26. “We have als

European Energy A/S: Notice to convene ordinary general meeting28.2.2024 23:08:42 CET | Press release

Company announcement 7/2024 (28.02.2024) The Board of Directors of the Company hereby convenes an ordinary general meeting of the Company, to be held on: Thursday 14 March 2024 at 09:30 CET at the address of the Company, Gyngemose Parkvej 50, 2860 Søborg, Denmark and electronically on Teams Agenda: Election of Chair of the Annual General Meeting.Report on the activities of the Company.Presentation of the annual report with the auditors’ report for approval and discharge of the Board of Directors and the Executive Board.Resolution on the appropriation of profit or treatment of loss according to the approved annual report.Election of members to the Board of Directors.Decision regarding remuneration to the Board of Directors for the financial year 2024. Amendments to the article of association.Election of Auditor(s).AOB. Attachment Notice to convene ordinary general meeting

European Energy A/S: Full-year Financial Report 2023 - Shows resilience and growth in turbulent year28.2.2024 23:00:49 CET | Press release

Company announcement 6/2024 (28.02.2024) European Energy announces its financial report for the full-year 2023. Highlights: Record high EBITDA of EUR 178m represents a 27% increase, achieving our 2023 financial outlook. This result was driven largely by the sale of energy parks and projects, including a revaluation gain from Kassø, partly offset by increasing staff and external expenses due to higher activityRecord Electricity Generation: In 2023, our total renewable energy production reached a record high level of 1,870 GWh or +140% compared to 2022. As power prices in many markets more than halved during 2023, our power sales profit was stable compared to 2022Profitable Power-to-X Projects: Demonstrated through the profitable farm down of the world's largest e-methanol project in Kassø to Mitsui. Another achievement in 2023 was securing over DKK 1bn from Danish green hydrogen price premium tenders, ensuring significant subsidies for the next decade for three new Danish PtX projects.V

Amlan International Forges Strategic Partnership with Grupo Profil as its Newest Latin American Distributor, Amplifying Access to Innovative Gut Health Solutions for Protein Producers28.2.2024 23:00:42 CET | Press release

CHICAGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Amlan® International, the animal health division of Oil-Dri® Corporation of America, is excited to announce its partnership with Grupo Profil as the newest distributor for the Latin American region. Known for their dedication to providing natural alternatives and comprehensive solutions in prophylaxis and nutrition to the regional livestock sector, Grupo Profil will now offer Amlan's innovative, natural feed additives to animal health retailers across Guatemala, El Salvador, and Honduras. Amlan will collaborate with Profil to expand its impact on the growing Latin American market. Profil's commitment to delivering advanced, effective solutions to the market perfectly aligns with Amlan's mission to enhance animal health and productivity while reducing reliance on antibiotics and synthetic additives. Through this partnership, Profil will distribute Amlan’s Calibrin®-Z, Calibrin®-A, Varium®, and NeoPrime®, catering to the poultry, swine, aquacult

Havila Kystruten AS: Fourth quarter 2023 accounts28.2.2024 22:24:49 CET | Press release

Summary The company has completed its first quarter with full operation of all four ships. Revenue in the fourth quarter was MNOK 249. Due to late clarification on the delivery of the last two ships, the revenue side is somewhat lower than if the pre-sale had started earlier. The last quarter of 2023 ended with an average fleet occupancy of 60%, an average cabin rate (ACR) of NOK 3,100 and a utilization rate of 1.8 per cabin. Occupancy and average price per cabin are higher than the fourth quarter of 2022, but are somewhat lower than the third quarter due to lower demand in the autumn and winter months. EBITDA was negative by MNOK 33.2 in the fourth quarter and MNOK 179 for the full year. Operating costs amounted to MNOK 283 in the fourth quarter and are mainly ordinary operating costs for operating four ships. Some of the operating costs are related to the number of passengers, while the largest cost items are not significantly affected by occupancy. MNOK 18 relates to extraordinary m

HiddenA line styled icon from Orion Icon Library.Eye